Skip to main content

Table 1 Clinical information on Patients and corresponding NSG Xenografts

From: PDX models reflect the proteome landscape of pediatric acute lymphoblastic leukemia but divert in select pathways

  Patient and disease characteristics at initial diagnosis Disease characteristics of clinical samples (Dx and R) xenografted in NSG mice Xenograft characteristics
  Patient ID Diagnosis Sex Age (years) Cytogenetics Risk group Sample Time-Point Time to Disease Progression (months) Risk Group Cytogenetics* MNC Source Patient Blast Content (%) Injected viable MNCs Xenograft ID Time to Progression in PDX (days) PDX Tumor Content (%)
1 B-01-Dx B-ALL F 11 Constitutional trisomy 21
Trisomy X
HR Dx NA - Constitutional trisomy 21
Trisomy X
BM 94 1M B-01-Dx-PDX 146 92
2 B-02-Dx B-ALL F 3 Variant t(12;21) with ETV6/RUNX1 fusion
Multiple chromosomal rearrangments [t(X;2), t(4;12;21), t(5;7), t(10;11), t(16;19)]
HR Dx NA - Variant t(12;21) with ETV6/RUNX1 fusion
Multiple chromosomal rearrangments [t(X;2), t(4;12;21), t(5;7), t(10;11), t(16;19)]
BM 97 1M B-02-Dx-PDXa 146 99
   1M B-02-Dx-PDXb 130 98
3 B-03-Dx B-ALL F 2 Hemizygous deletion of p16 (CDKN2A) locus, del(9) AR Dx NA - Hemizygous deletion of p16 (CDKN2A) locus, del(9) BM 93 1M B-03-Dx-PDXa 87 ND
   1M B-03-Dx-PDXb 82 94
4 B-04-Dx B-ALL F 15 Cryptic t(12;21) with ETV6/RUNX1 fusion, Monosomy X,
Complex abnormal karyotype, [(t,4;12)]
HR Dx NA - Cryptic t(12;21) with ETV6/RUNX1 fusion, Monosomy X,
Complex abnormal karyotype, [(t,4;12)]
BM 95 1M B-04-Dx-PDX 361 95
5 B-05-R1 B-ALL post B-cell Lymphoma F 3 ND - R1 17 VHR Normal: 46,XX BM 68 1M B-05-R1-PDX 255 98
6 B-06-R2 B-ALL M 13 ND - R2 31 HR Homozygous deletion of CDKN2A locus
Complex karyotype [t8;9), t(13;17)]
BM 96 1M B-06-R2-PDXa 246 96
  1M B-06-R2-PDXb 240 98
7 B-06-R3 15 ND - R3 15 VHR Homozygous deletion of CDKN2A locus
Highly abnormal karyotype, [t(8;9), t(13;17)]
BM 90 1M B-06-R3-PDXa 158 92
  1M B-06-R3-PDXb ND ND
8 B-07-R3 B-ALL M 15 NORMAL: 46,XY - R3 12 VHR Homozygous deletion of CDKN2A locus Blood Numerous 1.6M B-07-R3-PDXa 46 94
  1.6M B-07-R3-PDXb 46 92
9 B-08-R2 B-ALL F 17 Trisomy X - R2 24 VHR Trisomy X RUNX1 amplification
Complex karyotype, [t(2;12), t(3;8), t(4;17;14), t(12;15), t(12;16)]
BM 94 1M B-08-R2-PDX 137 ND
10 T-01-Dx T-ALL M 5 Cryptic heterozygous deletion of CDKN2A HR Dx NA   Cryptic heterozygous deletion of CDKN2A BM 81 1M T-01-Dx-PDX 69 92
11 T-01-R1 T-ALL 5 - R1 60 HR Cryptic heterozygous deletion of CDKN2A BM 2 1M T-01-R1-PDXa 61 98
  (Isolated CNS relapse with 2% bone marrow infiltration) 1M T-01-R1-PDXb 55 ND
12 T-02-Dx T-ALL M 13 Monosomy 14
Interstitial deletion of chr. 6(q)
HR Dx NA - Monosomy 14
Interstitial deletion of chr. 6(q)
BM 90 0.7M T-02-Dx-PDX 240 99
13 T-03-Dx metastatic T-cell lymphoblastic lymphoma F 10 Hyperdiploidy (+6, +8, +10, +11, +13, +19, +19) ND Dx NA - Hyperdiploidy (+6, +8, +10, +11, +13, +19, +19) BM 8 1M T-03-Dx-PDX 208 94
14 NL-01 GATA2 mutation M 6 Normal: 46, XY NA Non-leukemic - NA - BM 0 NA NA NA NA
15 NL-02 Thrombocytopenia & macrocytosis F 17 Normal: 46, XX NA Non-leukemic - NA - BM 0 NA NA NA NA
  1. Abbreviations: ND No data / Not determined, NA Not applicable, M Male, F Female, CNS central nervous system, NSG Non-obese diabetic scid gamma immunodeficient mouse, MNC mononuclear cell, Dx diagnosis, R relapse, R(1,2,3) = first, second, third relapse
  2. Risk group = High Risk (HR), Average Risk (AR), Very High Risk (VHR)
  3. Cytogenetics*: this is the same for diagnosis samples, but varies for relapse cases where the cytogenetics differed from that at diagnosis